DREPAMASSE Study – Evaluation of a Newborn Screening for Sickle Cell Disease by Tandem Mass Spectrometry

Study point of contact

David CHEILLAN, MD, PhD
04 72 12 96 88 ext +33
[email protected]
Dr Céline RENOUX, MD, PhD
04.27.85.65.94 ext +33
[email protected]

Locations

3 France sites

Age

< 27 Years

Study type

Observational

Gender

All

Interventions

Other

Compensation

Unknown

About the study

Three methods are actually used in newborn screening for sickle cell disease (SCD) in France:
isoelectric focusing, high performance liquid chromatography and capillary electrophoresis.
New technologies are currently under development such as Matrix Assisted Laser Desorption
Ionisation – Time of Flight (MALDI-TOF) and tandem mass spectrometry (MS/MS) using the SpOtOn
Diagnostics Reagent Kit available in United Kingdom only.

Zentech company (Liège, Belgium) is developing a package for SCD newborn screening using
MS/MS technology. The main objective of the present study will be to compare this new
technique with the technique actually used in the hospital center of Lille (sub-contractor
for SCD newborn screening of Lyon) and the haemoglobin analysis to test its accuracy
(sensitivity and specificity).

participation requirements

– Infants with SCD newborn screening conducted in the hospital center of Lyon

participation restrictions

– Insufficient quantity of sampling

– Parents’ opposition to their newborn’s participation in the study

Locations

  • Bron, France, Groupement Hospitalier Est - Hospices Civils de Lyon, 69677 [Not yet recruiting]
  • Lyon, France, Hôpital de la Croix Rousse, 69317 [Not yet recruiting]
  • Pierre-Bénite, France, Centre Hospitalier Lyon Sud, 69495 [Recruiting]
Last updated 2021-03-19 Enroll Now